Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00023240
DRKS00023240
Not yet recruiting
Not Applicable

Prostate-specific membrane antigen (PSMA) expression in ovarian carcinoma

niversitätsklinikum Freiburg Klinik für Frauenheilkunde0 sites100 target enrollmentOctober 8, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC56Malignant neoplasm of ovary

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C56
Sponsor
niversitätsklinikum Freiburg Klinik für Frauenheilkunde
Enrollment
100
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 8, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
niversitätsklinikum Freiburg Klinik für Frauenheilkunde

Eligibility Criteria

Inclusion Criteria

  • •Patients with histopathologically confirmed, invasive serous ovarian carcinoma are included in this study.

Exclusion Criteria

  • •missing declaration of consent
  • •other oncological disease
  • •Borderline tumor or other histological subtype (except the invasive serous ovarian carcinoma)
  • •Cytostatic therapy administered before the tissue sample is taken
  • •Radiotherapy performed before the tissue sample is taken

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Prostate-specific Membrane Antigen (PSMA) expression in cervical carcinomaC53.9Cervix uteri, unspecified
DRKS00023289niversitätsklinikum FreiburgKlinik für Frauenheilkunde100
Completed
Not Applicable
Prostate-specific Membrane Antigen (PSMA) expression in endometrial cancerC54Malignant neoplasm of corpus uteri
DRKS00025005niversitätsklinikum Freiburg Klinik für Frauenheilkunde61
Recruiting
Phase 2
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstructiometastatic castration-resistant prostate cancerCancer - Prostate
ACTRN12621000611820St Vincent's Hospital, Sydney22
Recruiting
Phase 2
Expression of prostate specific membrane antigen (PSMA) in soft tissue sarcomas and urothelial cell carcinomas: implications for tumour-specific molecular imaging and treatment?bladder cancercohort 1: soft tissue cancercohort 2: transitional cell carcinomasoft tissue tumour1002838910004994
NL-OMON54064eids Universitair Medisch Centrum120
Not yet recruiting
Phase 1
Emerging digital imaging-guided theranostic therapy for newly diagnosed high risk prostate cancer patients: A feasibility studyProstate CancerCancer - Prostate
ACTRN12620001358932I-MED Radiology Network5